Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics.

Pade D, Jamei M, Turner DB, Mistry B, Martinez MN.

Eur J Pharm Biopharm. 2019 Aug;141:191-209. doi: 10.1016/j.ejpb.2019.05.024. Epub 2019 May 28.

PMID:
31150808
2.

What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing.

Polasek TM, Rostami-Hodjegan A, Yim DS, Jamei M, Lee H, Kimko H, Kim JK, Nguyen PTT, Darwich AS, Shin JG.

AAPS J. 2019 Jan 9;21(2):17. doi: 10.1208/s12248-018-0286-6.

PMID:
30627939
3.

VIVD: Virtual in vitro distribution model for the mechanistic prediction of intracellular concentrations of chemicals in in vitro toxicity assays.

Fisher C, Siméon S, Jamei M, Gardner I, Bois YF.

Toxicol In Vitro. 2019 Aug;58:42-50. doi: 10.1016/j.tiv.2018.12.017. Epub 2018 Dec 29.

4.

In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration.

Butler J, Hens B, Vertzoni M, Brouwers J, Berben P, Dressman J, Andreas CJ, Schaefer KJ, Mann J, McAllister M, Jamei M, Kostewicz E, Kesisoglou F, Langguth P, Minekus M, Müllertz A, Schilderink R, Koziolek M, Jedamzik P, Weitschies W, Reppas C, Augustijns P.

Eur J Pharm Biopharm. 2019 Mar;136:70-83. doi: 10.1016/j.ejpb.2018.12.010. Epub 2018 Dec 20.

5.

Biopharmaceutic IVIVE-Mechanistic Modeling of Single- and Two-Phase In Vitro Experiments to Obtain Drug-Specific Parameters for Incorporation Into PBPK Models.

Pathak SM, Schaefer KJ, Jamei M, Turner DB.

J Pharm Sci. 2019 Apr;108(4):1604-1618. doi: 10.1016/j.xphs.2018.11.034. Epub 2018 Nov 23.

6.

Fetal Physiologically Based Pharmacokinetic Models: Systems Information on the Growth and Composition of Fetal Organs.

Abduljalil K, Jamei M, Johnson TN.

Clin Pharmacokinet. 2019 Feb;58(2):235-262. doi: 10.1007/s40262-018-0685-y.

PMID:
29987449
7.

Correction: Predicting all-cause risk of 30-day hospital readmission using artificial neural networks.

Jamei M, Nisnevich A, Wetchler E, Sudat S, Liu E, Upadhyaya K.

PLoS One. 2018 May 17;13(5):e0197793. doi: 10.1371/journal.pone.0197793. eCollection 2018.

8.

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz.

Chetty M, Cain T, Wedagedera J, Rostami-Hodjegan A, Jamei M.

Front Pharmacol. 2018 Mar 27;9:247. doi: 10.3389/fphar.2018.00247. eCollection 2018.

9.

Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development.

Polak S, Romero K, Berg A, Patel N, Jamei M, Hermann D, Hanna D.

J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):457-467. doi: 10.1007/s10928-018-9580-2. Epub 2018 Mar 8.

10.

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.

Shebley M, Sandhu P, Emami Riedmaier A, Jamei M, Narayanan R, Patel A, Peters SA, Reddy VP, Zheng M, de Zwart L, Beneton M, Bouzom F, Chen J, Chen Y, Cleary Y, Collins C, Dickinson GL, Djebli N, Einolf HJ, Gardner I, Huth F, Kazmi F, Khalil F, Lin J, Odinecs A, Patel C, Rong H, Schuck E, Sharma P, Wu SP, Xu Y, Yamazaki S, Yoshida K, Rowland M.

Clin Pharmacol Ther. 2018 Jul;104(1):88-110. doi: 10.1002/cpt.1013. Epub 2018 Feb 2. Review.

11.

Development and applications of a physiologically-based model of paediatric oral drug absorption.

Johnson TN, Bonner JJ, Tucker GT, Turner DB, Jamei M.

Eur J Pharm Sci. 2018 Mar 30;115:57-67. doi: 10.1016/j.ejps.2018.01.009. Epub 2018 Jan 5.

PMID:
29309876
12.

Real Patient and its Virtual Twin: Application of Quantitative Systems Toxicology Modelling in the Cardiac Safety Assessment of Citalopram.

Patel N, Wiśniowska B, Jamei M, Polak S.

AAPS J. 2017 Nov 27;20(1):6. doi: 10.1208/s12248-017-0155-8.

PMID:
29181593
13.

In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole.

Hens B, Pathak SM, Mitra A, Patel N, Liu B, Patel S, Jamei M, Brouwers J, Augustijns P, Turner DB.

Mol Pharm. 2017 Dec 4;14(12):4321-4333. doi: 10.1021/acs.molpharmaceut.7b00396. Epub 2017 Sep 5.

PMID:
28817288
14.

Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.

Pathak SM, Ruff A, Kostewicz ES, Patel N, Turner DB, Jamei M.

Mol Pharm. 2017 Dec 4;14(12):4305-4320. doi: 10.1021/acs.molpharmaceut.7b00406. Epub 2017 Aug 25.

15.

Predicting all-cause risk of 30-day hospital readmission using artificial neural networks.

Jamei M, Nisnevich A, Wetchler E, Sudat S, Liu E.

PLoS One. 2017 Jul 14;12(7):e0181173. doi: 10.1371/journal.pone.0181173. eCollection 2017. Erratum in: PLoS One. 2018 May 17;13(5):e0197793.

16.

Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop.

Zhang X, Duan J, Kesisoglou F, Novakovic J, Amidon GL, Jamei M, Lukacova V, Eissing T, Tsakalozou E, Zhao L, Lionberger R.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):492-495. doi: 10.1002/psp4.12204. Epub 2017 Jul 11.

17.
18.

The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model.

Musther H, Harwood MD, Yang J, Turner DB, Rostami-Hodjegan A, Jamei M.

J Pharm Sci. 2017 Sep;106(9):2826-2838. doi: 10.1016/j.xphs.2017.05.003. Epub 2017 May 8.

PMID:
28495566
19.

Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon.

Pade D, Jamei M, Rostami-Hodjegan A, Turner DB.

Biopharm Drug Dispos. 2017 Mar;38(2):94-114. doi: 10.1002/bdd.2072.

PMID:
28214380
20.

Prediction of liver volume - a population-based approach to meta-analysis of paediatric, adult and geriatric populations - an update.

Small BG, Wendt B, Jamei M, Johnson TN.

Biopharm Drug Dispos. 2017 May;38(4):290-300. doi: 10.1002/bdd.2063. Epub 2017 Mar 2.

PMID:
28084034
21.

Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept.

Abbasi M, Small BG, Patel N, Jamei M, Polak S.

Toxicol Mech Methods. 2017 Feb;27(2):88-99. doi: 10.1080/15376516.2016.1256460. Epub 2016 Nov 23.

PMID:
27813448
22.

A Tutorial on Pharmacodynamic Scripting Facility in Simcyp.

Abduljalil K, Edwards D, Barnett A, Rose RH, Cain T, Jamei M.

CPT Pharmacometrics Syst Pharmacol. 2016 Sep;5(9):455-65. doi: 10.1002/psp4.12102. Epub 2016 Aug 29. No abstract available.

23.

Comment on "In Silico Modeling of Gastrointestinal Drug Absorption: Predictive Performance of Three Physiologically-Based Absorption Models".

Turner DB, Liu B, Patel N, Pathak SM, Polak S, Jamei M, Dressman J, Rostami-Hodjegan A.

Mol Pharm. 2017 Jan 3;14(1):336-339. doi: 10.1021/acs.molpharmaceut.6b00469. Epub 2016 Dec 16. No abstract available.

PMID:
27392013
24.

Examining the Use of a Mechanistic Model to Generate an In Vivo/In Vitro Correlation: Journey Through a Thought Process.

Mistry B, Patel N, Jamei M, Rostami-Hodjegan A, Martinez MN.

AAPS J. 2016 Sep;18(5):1144-1158. doi: 10.1208/s12248-016-9930-1. Epub 2016 Jun 16.

PMID:
27312260
25.
27.

Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic Model.

Almond LM, Mukadam S, Gardner I, Okialda K, Wong S, Hatley O, Tay S, Rowland-Yeo K, Jamei M, Rostami-Hodjegan A, Kenny JR.

Drug Metab Dispos. 2016 Jun;44(6):821-32. doi: 10.1124/dmd.115.066845. Epub 2016 Mar 29. Erratum in: Drug Metab Dispos. 2016 Jun;44(6):877.

28.

Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.

Burt HJ, Neuhoff S, Almond L, Gaohua L, Harwood MD, Jamei M, Rostami-Hodjegan A, Tucker GT, Rowland-Yeo K.

Eur J Pharm Sci. 2016 Jun 10;88:70-82. doi: 10.1016/j.ejps.2016.03.020. Epub 2016 Mar 25.

29.

How Does In Vivo Biliary Elimination of Drugs Change with Age? Evidence from In Vitro and Clinical Data Using a Systems Pharmacology Approach.

Johnson TN, Jamei M, Rowland-Yeo K.

Drug Metab Dispos. 2016 Jul;44(7):1090-8. doi: 10.1124/dmd.115.068643. Epub 2016 Feb 9.

PMID:
26862026
30.

Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs.

Gaohua L, Wedagedera J, Small BG, Almond L, Romero K, Hermann D, Hanna D, Jamei M, Gardner I.

CPT Pharmacometrics Syst Pharmacol. 2015 Oct;4(10):605-13. doi: 10.1002/psp4.12034. Epub 2015 Oct 9.

31.

A Bottom-Up Whole-Body Physiologically Based Pharmacokinetic Model to Mechanistically Predict Tissue Distribution and the Rate of Subcutaneous Absorption of Therapeutic Proteins.

Gill KL, Gardner I, Li L, Jamei M.

AAPS J. 2016 Jan;18(1):156-70. doi: 10.1208/s12248-015-9819-4. Epub 2015 Sep 25.

PMID:
26408308
32.

Are Physiologically Based Pharmacokinetic Models Reporting the Right C(max)? Central Venous Versus Peripheral Sampling Site.

Musther H, Gill KL, Chetty M, Rostami-Hodjegan A, Rowland M, Jamei M.

AAPS J. 2015 Sep;17(5):1268-79. doi: 10.1208/s12248-015-9796-7. Epub 2015 Jun 23.

33.

Quantitative in vitro to in vivo extrapolation of tissues toxicity.

Hamon J, Renner M, Jamei M, Lukas A, Kopp-Schneider A, Bois FY.

Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):203-16. doi: 10.1016/j.tiv.2015.01.011. Epub 2015 Feb 9.

PMID:
25678044
34.

Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach.

Johnson TN, Salem F, Jamei M, Rostami-Hodjegan A.

Clin Pharmacokinet. 2015 May;54(5):567-8. doi: 10.1007/s40262-015-0247-5. No abstract available.

PMID:
25676442
35.

Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model.

Chetty M, Li L, Rose R, Machavaram K, Jamei M, Rostami-Hodjegan A, Gardner I.

Front Immunol. 2015 Jan 5;5:670. doi: 10.3389/fimmu.2014.00670. eCollection 2014.

36.

Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults.

Bonner JJ, Vajjah P, Abduljalil K, Jamei M, Rostami-Hodjegan A, Tucker GT, Johnson TN.

Biopharm Drug Dispos. 2015 May;36(4):245-57. doi: 10.1002/bdd.1937. Epub 2015 Feb 12.

37.

Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variability.

Chetty M, Rose RH, Abduljalil K, Patel N, Lu G, Cain T, Jamei M, Rostami-Hodjegan A.

Front Pharmacol. 2014 Nov 26;5:258. doi: 10.3389/fphar.2014.00258. eCollection 2014.

38.

Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.

Mishra H, Polak S, Jamei M, Rostami-Hodjegan A.

CPT Pharmacometrics Syst Pharmacol. 2014 Aug 13;3:e130. doi: 10.1038/psp.2014.26.

39.

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.

Rose RH, Neuhoff S, Abduljalil K, Chetty M, Rostami-Hodjegan A, Jamei M.

CPT Pharmacometrics Syst Pharmacol. 2014 Jul 9;3:e124. doi: 10.1038/psp.2014.24.

40.

Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.

Li L, Gardner I, Dostalek M, Jamei M.

AAPS J. 2014 Sep;16(5):1097-109. doi: 10.1208/s12248-014-9640-5. Epub 2014 Jul 9.

41.

Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model.

Abduljalil K, Jamei M, Rostami-Hodjegan A, Johnson TN.

AAPS J. 2014 May;16(3):568-76. doi: 10.1208/s12248-014-9592-9. Epub 2014 Apr 4.

42.

Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions.

Wu F, Gaohua L, Zhao P, Jamei M, Huang SM, Bashaw ED, Lee SC.

Pharm Res. 2014 Aug;31(8):1919-29. doi: 10.1007/s11095-013-1293-z. Epub 2014 Mar 4.

PMID:
24590877
43.

Incorporating Target Shedding Into a Minimal PBPK-TMDD Model for Monoclonal Antibodies.

Li L, Gardner I, Rose R, Jamei M.

CPT Pharmacometrics Syst Pharmacol. 2014 Jan 29;3:e96. doi: 10.1038/psp.2013.73.

44.

PBPK models for the prediction of in vivo performance of oral dosage forms.

Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O, Jamei M, Lloyd R, Pepin X, Rostami-Hodjegan A, Sjögren E, Tannergren C, Turner DB, Wagner C, Weitschies W, Dressman J.

Eur J Pharm Sci. 2014 Jun 16;57:300-21. doi: 10.1016/j.ejps.2013.09.008. Epub 2013 Sep 21. Review.

PMID:
24060672
45.

Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine.

Patel N, Polak S, Jamei M, Rostami-Hodjegan A, Turner DB.

Eur J Pharm Sci. 2014 Jun 16;57:240-9. doi: 10.1016/j.ejps.2013.09.006. Epub 2013 Sep 21.

PMID:
24060671
46.

Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine.

Darwich AS, Pade D, Rowland-Yeo K, Jamei M, Asberg A, Christensen H, Ashcroft DM, Rostami-Hodjegan A.

CPT Pharmacometrics Syst Pharmacol. 2013 Jun 12;2:e47. doi: 10.1038/psp.2013.23.

47.

A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporine.

Jamei M, Bajot F, Neuhoff S, Barter Z, Yang J, Rostami-Hodjegan A, Rowland-Yeo K.

Clin Pharmacokinet. 2014 Jan;53(1):73-87. doi: 10.1007/s40262-013-0097-y.

48.

A novel ultrasound assisted method in synthesis of NZVI particles.

Jamei MR, Khosravi MR, Anvaripour B.

Ultrason Sonochem. 2014 Jan;21(1):226-33. doi: 10.1016/j.ultsonch.2013.04.015. Epub 2013 May 22.

PMID:
23768647
49.

Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.

Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A.

J Pharm Sci. 2013 Sep;102(9):3145-60. doi: 10.1002/jps.23594. Epub 2013 May 22.

PMID:
23703021
50.

Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.

Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A.

J Pharm Sci. 2013 Sep;102(9):3161-73. doi: 10.1002/jps.23607. Epub 2013 May 19.

PMID:
23686764

Supplemental Content

Support Center